Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Erik S. Stroes, Paul D. Thompson, Alberto Corsini, Georgirene D. Vladutiu, Frederick J. Raal, Kausik K. Ray, Michael Roden, Evan Stein, Lale Tokgözoʇlu, Børge G. Nordestgaard, Eric Bruckert, Guy De Backer, Ronald M. Krauss, Ulrich Laufs, Raul D. Santos, Robert A. Hegele, G. Kees Hovingh, Lawrence A. Leiter, Francois Mach, Winfried MärzConnie B. Newman, Olov Wiklund, Terry A. Jacobson, Alberico L. Catapano, M. John Chapman, Henry N. Ginsberg

Research output: Contribution to journalArticle

538 Citations (Scopus)

Abstract

Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of statins, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses. Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels, with a prevalence of 7-29% in registries and observational studies. Preclinical studies show that statins decrease mitochondrial function, attenuate energy production, and alter muscle protein degradation, thereby providing a potential link between statins and muscle symptoms; controlled mechanistic and genetic studies in humans are necessary to further understanding. The Panel proposes to identify SAMS by symptoms typical of statin myalgia (i.e. muscle pain or aching) and their temporal association with discontinuation and response to repetitive statin re-challenge. In people with SAMS, the Panel recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets. The Panel recommends a structured work-up to identify individuals with clinically relevant SAMS generally to at least three different statins, so that they can be offered therapeutic regimens to satisfactorily address their cardiovascular risk. Further research into the underlying pathophysiological mechanisms may offer future therapeutic potential.

Original languageEnglish
Pages (from-to)1012-1022
Number of pages11
JournalEuropean Heart Journal
Volume36
Issue number17
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Consensus
Muscles
Therapeutics
Myalgia
Muscular Diseases
Creatine Kinase
Maximum Tolerated Dose
Muscle Proteins

Keywords

  • Cholesterol
  • Consensus statement
  • Lipids
  • Mitochondrial
  • Musclesymptoms
  • Myalgia
  • Myopathy
  • Statin
  • Statin intolerance

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Statin-associated muscle symptoms : impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. / Stroes, Erik S.; Thompson, Paul D.; Corsini, Alberto; Vladutiu, Georgirene D.; Raal, Frederick J.; Ray, Kausik K.; Roden, Michael; Stein, Evan; Tokgözoʇlu, Lale; Nordestgaard, Børge G.; Bruckert, Eric; De Backer, Guy; Krauss, Ronald M.; Laufs, Ulrich; Santos, Raul D.; Hegele, Robert A.; Hovingh, G. Kees; Leiter, Lawrence A.; Mach, Francois; März, Winfried; Newman, Connie B.; Wiklund, Olov; Jacobson, Terry A.; Catapano, Alberico L.; Chapman, M. John; Ginsberg, Henry N.

In: European Heart Journal, Vol. 36, No. 17, 01.05.2015, p. 1012-1022.

Research output: Contribution to journalArticle

Stroes, ES, Thompson, PD, Corsini, A, Vladutiu, GD, Raal, FJ, Ray, KK, Roden, M, Stein, E, Tokgözoʇlu, L, Nordestgaard, BG, Bruckert, E, De Backer, G, Krauss, RM, Laufs, U, Santos, RD, Hegele, RA, Hovingh, GK, Leiter, LA, Mach, F, März, W, Newman, CB, Wiklund, O, Jacobson, TA, Catapano, AL, Chapman, MJ & Ginsberg, HN 2015, 'Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management', European Heart Journal, vol. 36, no. 17, pp. 1012-1022. https://doi.org/10.1093/eurheartj/ehv043
Stroes, Erik S. ; Thompson, Paul D. ; Corsini, Alberto ; Vladutiu, Georgirene D. ; Raal, Frederick J. ; Ray, Kausik K. ; Roden, Michael ; Stein, Evan ; Tokgözoʇlu, Lale ; Nordestgaard, Børge G. ; Bruckert, Eric ; De Backer, Guy ; Krauss, Ronald M. ; Laufs, Ulrich ; Santos, Raul D. ; Hegele, Robert A. ; Hovingh, G. Kees ; Leiter, Lawrence A. ; Mach, Francois ; März, Winfried ; Newman, Connie B. ; Wiklund, Olov ; Jacobson, Terry A. ; Catapano, Alberico L. ; Chapman, M. John ; Ginsberg, Henry N. / Statin-associated muscle symptoms : impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. In: European Heart Journal. 2015 ; Vol. 36, No. 17. pp. 1012-1022.
@article{ade54760082f4d4d9a570aaafa137b3b,
title = "Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management",
abstract = "Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of statins, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses. Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels, with a prevalence of 7-29{\%} in registries and observational studies. Preclinical studies show that statins decrease mitochondrial function, attenuate energy production, and alter muscle protein degradation, thereby providing a potential link between statins and muscle symptoms; controlled mechanistic and genetic studies in humans are necessary to further understanding. The Panel proposes to identify SAMS by symptoms typical of statin myalgia (i.e. muscle pain or aching) and their temporal association with discontinuation and response to repetitive statin re-challenge. In people with SAMS, the Panel recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets. The Panel recommends a structured work-up to identify individuals with clinically relevant SAMS generally to at least three different statins, so that they can be offered therapeutic regimens to satisfactorily address their cardiovascular risk. Further research into the underlying pathophysiological mechanisms may offer future therapeutic potential.",
keywords = "Cholesterol, Consensus statement, Lipids, Mitochondrial, Musclesymptoms, Myalgia, Myopathy, Statin, Statin intolerance",
author = "Stroes, {Erik S.} and Thompson, {Paul D.} and Alberto Corsini and Vladutiu, {Georgirene D.} and Raal, {Frederick J.} and Ray, {Kausik K.} and Michael Roden and Evan Stein and Lale Tokg{\"o}zoʇlu and Nordestgaard, {B{\o}rge G.} and Eric Bruckert and {De Backer}, Guy and Krauss, {Ronald M.} and Ulrich Laufs and Santos, {Raul D.} and Hegele, {Robert A.} and Hovingh, {G. Kees} and Leiter, {Lawrence A.} and Francois Mach and Winfried M{\"a}rz and Newman, {Connie B.} and Olov Wiklund and Jacobson, {Terry A.} and Catapano, {Alberico L.} and Chapman, {M. John} and Ginsberg, {Henry N.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1093/eurheartj/ehv043",
language = "English",
volume = "36",
pages = "1012--1022",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "17",

}

TY - JOUR

T1 - Statin-associated muscle symptoms

T2 - impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

AU - Stroes, Erik S.

AU - Thompson, Paul D.

AU - Corsini, Alberto

AU - Vladutiu, Georgirene D.

AU - Raal, Frederick J.

AU - Ray, Kausik K.

AU - Roden, Michael

AU - Stein, Evan

AU - Tokgözoʇlu, Lale

AU - Nordestgaard, Børge G.

AU - Bruckert, Eric

AU - De Backer, Guy

AU - Krauss, Ronald M.

AU - Laufs, Ulrich

AU - Santos, Raul D.

AU - Hegele, Robert A.

AU - Hovingh, G. Kees

AU - Leiter, Lawrence A.

AU - Mach, Francois

AU - März, Winfried

AU - Newman, Connie B.

AU - Wiklund, Olov

AU - Jacobson, Terry A.

AU - Catapano, Alberico L.

AU - Chapman, M. John

AU - Ginsberg, Henry N.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of statins, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses. Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels, with a prevalence of 7-29% in registries and observational studies. Preclinical studies show that statins decrease mitochondrial function, attenuate energy production, and alter muscle protein degradation, thereby providing a potential link between statins and muscle symptoms; controlled mechanistic and genetic studies in humans are necessary to further understanding. The Panel proposes to identify SAMS by symptoms typical of statin myalgia (i.e. muscle pain or aching) and their temporal association with discontinuation and response to repetitive statin re-challenge. In people with SAMS, the Panel recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets. The Panel recommends a structured work-up to identify individuals with clinically relevant SAMS generally to at least three different statins, so that they can be offered therapeutic regimens to satisfactorily address their cardiovascular risk. Further research into the underlying pathophysiological mechanisms may offer future therapeutic potential.

AB - Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of statins, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses. Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels, with a prevalence of 7-29% in registries and observational studies. Preclinical studies show that statins decrease mitochondrial function, attenuate energy production, and alter muscle protein degradation, thereby providing a potential link between statins and muscle symptoms; controlled mechanistic and genetic studies in humans are necessary to further understanding. The Panel proposes to identify SAMS by symptoms typical of statin myalgia (i.e. muscle pain or aching) and their temporal association with discontinuation and response to repetitive statin re-challenge. In people with SAMS, the Panel recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets. The Panel recommends a structured work-up to identify individuals with clinically relevant SAMS generally to at least three different statins, so that they can be offered therapeutic regimens to satisfactorily address their cardiovascular risk. Further research into the underlying pathophysiological mechanisms may offer future therapeutic potential.

KW - Cholesterol

KW - Consensus statement

KW - Lipids

KW - Mitochondrial

KW - Musclesymptoms

KW - Myalgia

KW - Myopathy

KW - Statin

KW - Statin intolerance

UR - http://www.scopus.com/inward/record.url?scp=84927742065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927742065&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehv043

DO - 10.1093/eurheartj/ehv043

M3 - Article

AN - SCOPUS:84927742065

VL - 36

SP - 1012

EP - 1022

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 17

ER -